2012
Patterns of Use and Short-Term Complications of Breast Brachytherapy in the National Medicare Population From 2008–2009
Presley CJ, Soulos PR, Herrin J, Roberts KB, Yu JB, Killelea B, Lesnikoski BA, Long JB, Gross CP. Patterns of Use and Short-Term Complications of Breast Brachytherapy in the National Medicare Population From 2008–2009. Journal Of Clinical Oncology 2012, 30: 4302-4307. PMID: 23091103, PMCID: PMC3675700, DOI: 10.1200/jco.2012.43.5297.Peer-Reviewed Original ResearchConceptsWhole breast irradiationHospital referral regionsBone complicationsClinical characteristicsSkin complicationsEarly-stage breast cancerNational treatment patternsPercent of patientsShort-term complicationsBreast-conserving surgeryNational Medicare populationComplication rateTreatment patternsAge 66Breast cancerReferral regionsMedicare populationPatterns of useComplicationsMedicare beneficiariesTreatment groupsClinical practiceBreast brachytherapyBrachytherapyInstrumental variable analysisShort-term complications and use of breast brachytherapy in the national Medicare population in 2008-2009.
Presley C, Soulos P, Herrin J, Roberts K, Yu J, Killelea B, Lesnikoski B, Long J, Gross C. Short-term complications and use of breast brachytherapy in the national Medicare population in 2008-2009. Journal Of Clinical Oncology 2012, 30: 1030-1030. DOI: 10.1200/jco.2012.30.15_suppl.1030.Peer-Reviewed Original ResearchWhole breast irradiationHospital referral regionsBone complicationsClinical characteristicsSkin complicationsReferral regionsEarly-stage breast cancerNational treatment patternsOne-year overallReceipt of chemotherapyNumber of comorbiditiesShort-term complicationsDeep tissuesNational Medicare populationAdjuvant radiationComplication rateTreatment patternsDiagnosis codesBreast cancerMedicare claimsMedicare populationComplicationsMedicare beneficiariesTreatment groupsClinical practiceAssessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population
Soulos PR, Yu JB, Roberts KB, Raldow AC, Herrin J, Long JB, Gross CP. Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population. Journal Of Clinical Oncology 2012, 30: 1601-1607. PMID: 22393088, PMCID: PMC3383112, DOI: 10.1200/jco.2011.39.4890.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBreast NeoplasmsCombined Modality TherapyDisease-Free SurvivalFemaleHumansLife ExpectancyMastectomy, SegmentalMedicareNeoplasm InvasivenessNeoplasm StagingPrognosisRadiotherapy, AdjuvantRisk AssessmentSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsUse of RTAdjuvant radiation therapyRadiation therapyOlder womenRT useLife expectancyBreast cancerMedicare populationEnd Results-Medicare dataStage I breast cancerStrata of ageCooperative group trialsI breast cancerBreast cancer careStrata of patientsHealth system characteristicsLog-binomial regressionShort life expectancySample of womenTreatment guidelinesCancer careInclusion criteriaGroup trialsMedicare beneficiariesClinical practice
2011
The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers
Chen Z, Roberts K, Decker R, Pathare P, Rockwell S, Nath R. The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers. Physics In Medicine And Biology 2011, 56: 4895-4912. PMID: 21772076, PMCID: PMC3154133, DOI: 10.1088/0031-9155/56/15/016.Peer-Reviewed Original ResearchConceptsPermanent interstitial brachytherapyProstate edemaProstate cancerEffects of edemaTumor control probabilityImpact of edemaInterstitial brachytherapyCell survivalEarly-stage prostate cancerControl probabilityStage prostate cancerCurrent clinical practiceProstate cancer cellsTumor cell proliferationInterstitial brachytherapy treatmentSublethal damage repairDose variationTumor cell survivalTumor characteristicsTumor controlClinical impactEdemaEdema evolutionClinical practiceProstate gland
1999
Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103
Peschel R, Chen Z, Roberts K, Nath R. Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103. International Journal Of Cancer 1999, 7: 278-288. PMID: 10580897, DOI: 10.1002/(sici)1520-6823(1999)7:5<278::aid-roi3>3.0.co;2-3.Peer-Reviewed Original ResearchMeSH KeywordsActuarial AnalysisBrachytherapyCell DeathFollow-Up StudiesForecastingHumansIodine RadioisotopesLongitudinal StudiesMaleModels, BiologicalNeoplasm StagingPalladiumProbabilityProstatic NeoplasmsRadioisotopesRadiopharmaceuticalsRadiotherapy DosageRelative Biological EffectivenessRetrospective StudiesTreatment OutcomeConceptsLong-term complicationsMinimum tumor dosesComplication ratePd-103Lower overall complication ratePalladium-103Long-term complication rateIodine-125Overall complication rateHigh complication rateProstate cancer patientsProstate implantsActuarial probabilityGrade IIILog10 cell killCancer patientsVs. 6Tumor dosesClinical practiceCell killProstate cancer brachytherapyEffective doseNormal tissuesPatientsTissue beds